comparemela.com

Latest Breaking News On - Bioxcel therapeutics - Page 1 : comparemela.com

BioXcel Therapeutics, Inc (NASDAQ:BTAI) CEO Vimal Mehta Sells 126,014 Shares

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 126,014 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total transaction of $205,402.82. Following the transaction, the chief executive officer now directly owns 7,811,515 shares of the […]

Insider Selling: BioXcel Therapeutics, Inc (NASDAQ:BTAI) CEO Sells 126,014 Shares of Stock

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 126,014 shares of BioXcel Therapeutics stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total transaction of $205,402.82. Following the transaction, the chief executive officer now directly owns 7,811,515 shares […]

BioXcel Therapeutics, Inc (NASDAQ:BTAI) Short Interest Up 8 7% in May

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,630,000 shares, a growth of 8.7% from the April 30th total of 1,500,000 shares. Based on an average daily trading volume, of 584,400 shares, the days-to-cover […]

Experimental therapy shows promise in pancreatic cancer clinical trial

Clinicians at Georgetown University s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a Phase II clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28.05.2024 - NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) - BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced . Seite 1

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.